Would you consider TPO agonists for thrombocytopenia from low risk MDS?

There are randomized data supporting the use of TPO agonists in low-risk MDS with thrombocytopenia. A phase II study of eltrombopag vs placebo demonstrated a platelet response in ~40% of patients treated with eltrombopag and no increased risk of disease progression/AML evolution between the eltrombo...